Thomas E. Malcolm, PhD

Thomas Malcolm Ph.D. is providing advice on Gene Editing, Cell Therapy and Infectious Disease to FPG with respect to clinical and scientific matters related to current and prospective clients.

Dr. Malcolm currently serves as the founding President, CEO and CSO of Iron Hills Therapeutics Inc., a company that is developing a novel technology to resolve the challenges associated in treating solid tumor cancers with CAR cell therapies.

Dr. Malcolm also serves as the COO, and co-founding Board Member for Kermode Biotechnologies Inc., a company dedicated to treating and protecting livestock animals from viruses that have potential to cross into and infect humans, a phenomenon known as zoonosis.

In addition to his executive roles, Thomas is a member of the SAB for Cila Therapeutics Inc., located in Boston MA, a company developing inhaled therapies for the treatment of a rare genetic disorder, Primary Ciliary Dyskinesia (PCD), a scientific advisor and former CSO for BioMark Diagnostics Inc., a company developing metabolomic diagnostics in Vancouver, Canada, and has consulted for Aridis Pharmaceuticals, a CRISPR-based antibody vaccine development company, located in San Jose, California.

Dr. Malcolm served as the CEO and CSO of Excision Biotherapeutics Inc., CRISPR company that he founded, focused on CRISPR gene editing for the treatment of human viral infectious diseases. Dr. Malcolm also founded Criterion BioScience Research Group in 2012, a life sciences advisory group looking at emergent biotechnologies.

Dr. Malcolm has published his work on viruses and cancers in multiple high impact journals. He is also a co-inventor on numerous patents. Thomas earned his Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia, Vancouver, Canada and continued his studies as a postdoctoral fellow at Sloan Kettering Memorial Cancer Center and Mount Sinai School of Medicine in New York, NY.